Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus TAMSULOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus TAMSULOSIN HYDROCHLORIDE.
ALFUZOSIN HYDROCHLORIDE vs TAMSULOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder neck, and prostatic urethra, causing smooth muscle relaxation and improved urine flow.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. For patients who fail to respond to 0.4 mg after 2-4 weeks, dose may be increased to 0.8 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
9-13 hours in healthy subjects, but can increase to 14-16 hours in elderly patients. This supports once-daily dosing, though steady-state is reached by day 5.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Primarily hepatic metabolism (CYP3A4 and CYP2D6) followed by renal excretion. Approximately 75-90% of a dose is excreted in urine as inactive metabolites, with <10% as unchanged drug. Fecal excretion accounts for 10-15%.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker